I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| endothelial cell | 7 studies | 21% ± 5% | |
| platelet | 6 studies | 22% ± 4% | |
| epithelial cell | 5 studies | 27% ± 9% | |
| fibroblast | 5 studies | 20% ± 5% | |
| natural killer cell | 5 studies | 23% ± 6% | |
| CD16-negative, CD56-bright natural killer cell, human | 4 studies | 18% ± 1% | |
| lymphocyte | 4 studies | 19% ± 3% | |
| glutamatergic neuron | 4 studies | 29% ± 11% | |
| hematopoietic precursor cell | 3 studies | 21% ± 4% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 20% ± 2% | |
| GABAergic neuron | 3 studies | 30% ± 8% | |
| dendritic cell | 3 studies | 21% ± 4% | |
| abnormal cell | 3 studies | 20% ± 3% | |
| macrophage | 3 studies | 20% ± 1% | |
| transit amplifying cell | 3 studies | 35% ± 12% | |
| plasmacytoid dendritic cell | 3 studies | 22% ± 2% | |
| erythroblast | 3 studies | 31% ± 15% | |
| regulatory T cell | 3 studies | 18% ± 3% | |
| astrocyte | 3 studies | 23% ± 4% | |
| oligodendrocyte | 3 studies | 18% ± 2% | |
| CD8-positive, alpha-beta T cell | 3 studies | 19% ± 2% |
